WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 100270
CAS#: 114977-28-5 (anhydrous)
Description: Docetaxel, also known as RP-56976, is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
MedKoo Cat#: 100270
Name: Docetaxel
CAS#: 114977-28-5 (anhydrous)
Chemical Formula: C43H53NO14
Exact Mass: 807.34661
Molecular Weight: 807.8
Elemental Analysis: C, 63.93; H, 6.61; N, 1.73; O, 27.73.
Related CAS #: 148408-66-6 (hydrate) 114977-28-5 (anhydrous)
Synonym: RP56976; RP 56976; RP-56976. Docetaxel hydrate, brand name: Taxotere.
IUPAC/Chemical Name: (2aR,4S,4aS,6R,9S,11S,12S,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate.
InChi Key: ZDZOTLJHXYCWBA-JXHJHTFNSA-N
InChi Code: InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33?,35-,41+,42-,43+/m0/s1
SMILES Code: O=C(O[C@@H](C1[C@@]2(C)[C@@H](O)C[C@@]3([H])OC[C@]31OC(C)=O)[C@]4(O)C[C@H](OC([C@H](O)[C@@H](NC(OC(C)(C)C)=O)C5=CC=CC=C5)=O)C(C)=C(C4(C)C)[C@@H](O)C2=O)C6=CC=CC=C6
1: Conry RM. Response of follicular dendritic cell sarcoma to gemcitabine and docetaxel: report of two cases and literature review. Clin Sarcoma Res. 2014 Jun 28;4:6. doi: 10.1186/2045-3329-4-6. eCollection 2014. PubMed PMID: 25009738.
2: Park JC, Pratz CF, Tesfaye A, Brodsky RA, Antonarakis ES. The Effect of Therapeutic Anticoagulation on Overall Survival in Men Receiving First-Line Docetaxel Chemotherapy for Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2014 Jun 11. pii: S1558-7673(14)00118-9. doi: 10.1016/j.clgc.2014.04.008. [Epub ahead of print] PubMed PMID: 24999166.
3: Shiota M, Yokomizo A, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, Naito S. Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer. Support Care Cancer. 2014 Jul 5. [Epub ahead of print] PubMed PMID: 24996830.
4: Pan B, Chen D, Huang J, Wang R, Feng B, Song H, Chen L. HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma. Mol Cancer. 2014 Jul 5;13(1):165. [Epub ahead of print] PubMed PMID: 24996221.
5: Mizumachi T, Homma A, Kakizaki T, Sakashita T, Kano S, Hatakeyama H, Tsuchiya K, Yasuda K, Onimaru R, Shirato H, Taguchi J, Shimizu Y, Kinoshita I, Akita H, Fukuda S. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma. Int J Clin Oncol. 2014 Jul 5. [Epub ahead of print] PubMed PMID: 24993675.
6: Palma G, Conte C, Barbieri A, Bimonte S, Luciano A, Rea D, Ungaro F, Tirino P, Quaglia F, Arra C. Antitumor activity of PEGylated biodegradable nanoparticles for sustained release of docetaxel in triple-negative breast cancer. Int J Pharm. 2014 Jun 30;473(1-2):55-63. doi: 10.1016/j.ijpharm.2014.06.058. [Epub ahead of print] PubMed PMID: 24992317.
7: Tuxen MK, Cold S, Tange UB, Balslev E, Nielsen DL. Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer. Acta Oncol. 2014 Jul 3:1-6. [Epub ahead of print] PubMed PMID: 24991893.
8: Caffo O, De Giorgi U, Fratino L, Lo Re G, Basso U, D Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Macrini S, Messina C, Giordano M, Alesini D, Zustovich F, Fraccon AP, Vicario G, Conteduca V, Maines F, Galligioni E. Safety and Clinical Outcomes of Patients Treated with Abiraterone Acetate After Docetaxel: Results of the Italian Named Patient Programme. BJU Int. 2014 Jul 2. doi: 10.1111/bju.12857. [Epub ahead of print] PubMed PMID: 24988879.
9: Yang WC, Chen CH, Tang JY, Wu CF, Liu YC, Sun Y, Lin SF. Induction chemotherapy with docetaxel, Cisplatin and Fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma. Anticancer Res. 2014 Jul;34(7):3765-73. PubMed PMID: 24982400.
10: Matsumoto H, Kubota H, Higashida M, Yoden E, Hiratsuka J, Haruma K, Nakamura M, Hirai T. Docetaxel/ TS-1 with Radiation for Unresectable Squamous Cell Carcinoma of the Esophagus - A Phase II Trial. Anticancer Res. 2014 Jul;34(7):3759-63. PubMed PMID: 24982399.
